A new drug candidate targeting E. coli in the gut is in phase 1 clinical trials. According to a new paper it may improve the well-being of blood cancer patients and reduce their mortality rate from E. coli infections.
The latest updates from our most trusted sources
Scientists create CRISPR-based drug candidate targeting the microbiome
